Literature DB >> 6723384

The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes.

D A Mahler, D H Weinberg, C K Wells, A R Feinstein.   

Abstract

To improve the clinical measurement of dyspnea, we developed a baseline dyspnea index that rated the severity of dyspnea at a single state and a transition dyspnea index that denoted changes from that baseline. The scores in both indexes depend on ratings for three different categories: functional impairment; magnitude of task, and magnitude of effort. At the baseline state, dyspnea was rated in five grades from 0 (severe) to 4 (unimpaired) for each category. The ratings for each of the three categories were added to form a baseline focal score (range, 0 to 12). At the transition period, changes in dyspnea were rated by seven grades, ranging from -3 (major deterioration), to +3 (major improvement). The ratings for each of the three categories were added to form a transition focal score (range, -9 to +9). In 38 patients tested with respiratory disease, interobserver agreement was highly satisfactory for both indexes. The baseline focal score had the highest correlation (r = 0.60; P less than 0.001) with the 12-minute walking distance (12 MW), while significant, but lower, correlations existed for lung function. For the transition focal score, there was a significant correlation only with the 12 MW (r = 0.33; p = 0.04). These results indicate that dyspnea can receive a direct clinical rating that provides important information not disclosed by customary physiologic tests.

Entities:  

Mesh:

Year:  1984        PMID: 6723384     DOI: 10.1378/chest.85.6.751

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  235 in total

Review 1.  The prediction of benefit from pulmonary rehabilitation: setting, training intensity and the effect of selection by disability.

Authors:  M D Morgan
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

2.  Heterogeneity of pulmonary perfusion as a mechanistic image-based phenotype in emphysema susceptible smokers.

Authors:  Sara K Alford; Edwin J R van Beek; Geoffrey McLennan; Eric A Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

3.  Airway count and emphysema assessed by chest CT imaging predicts clinical outcome in smokers.

Authors:  Alejandro A Diaz; Clarissa Valim; Tsuneo Yamashiro; Raúl San José Estépar; James C Ross; Shin Matsuoka; Brian Bartholmai; Hiroto Hatabu; Edwin K Silverman; George R Washko
Journal:  Chest       Date:  2010-06-17       Impact factor: 9.410

Review 4.  Measuring quality of life in clinical trials: a taxonomy and review.

Authors:  G H Guyatt; S J Veldhuyzen Van Zanten; D H Feeny; D L Patrick
Journal:  CMAJ       Date:  1989-06-15       Impact factor: 8.262

Review 5.  Opioids for chronic refractory breathlessness: right patient, right route?

Authors:  David C Currow; Magnus Ekstrom; Amy P Abernethy
Journal:  Drugs       Date:  2014-01       Impact factor: 9.546

Review 6.  Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease: an expert consensus panel report.

Authors:  Kathleen W Wyrwich; Stephan D Fihn; William M Tierney; Kurt Kroenke; Ajit N Babu; Fredric D Wolinsky
Journal:  J Gen Intern Med       Date:  2003-03       Impact factor: 5.128

7.  Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

Authors:  Donald P Tashkin; Robert Elashoff; Philip J Clements; Michael D Roth; Daniel E Furst; Richard M Silver; Jonathan Goldin; Edgar Arriola; Charlie Strange; Marcy B Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fred Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky; Dinesh Khanna; Ning Li; Gang Li
Journal:  Am J Respir Crit Care Med       Date:  2007-08-23       Impact factor: 21.405

Review 8.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

9.  Value of theophylline treatment in patients handicapped by chronic obstructive lung disease.

Authors:  S E McKay; C A Howie; A H Thomson; B Whiting; G J Addis
Journal:  Thorax       Date:  1993-03       Impact factor: 9.139

Review 10.  Health-related quality of life in emphysema.

Authors:  Robert M Kaplan; Andrew L Ries
Journal:  Proc Am Thorac Soc       Date:  2008-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.